- XORTX Therapeutics Inc. (XRTX) has applied for international protection for its patent entitled “Compositions and Methods for Enhancing Anti-Viral Therapies”
- The patent is based on reviewed clinical data from XORTX partners
- The new patent filing proposes compositions of xanthine oxidase inhibitors, uric acid lowering agents and/or anti-viral agents
- A recent study results suggest that uric acid lowering can inhibit COVID-19 replication
- XORTX is not making any claims that it can eliminate, cure, or contain the COVID-19 coronavirus at this time
- XORTX Therapeutics Inc. (XRTX) is up 45.45 per cent trading at $2.24 per share as of 3:43 p.m. ET
XORTX Therapeutics (XRTX) has applied for a patent cooperation treaty (PCT) for its patent entitled “Compositions and Methods for Enhancing Anti-Viral Therapies”.
The patent is based on reviewed clinical data from XORTX partners. The data suggests that a therapeutic opportunity lies within addressing an abnormal purine metabolism (the most abundant metabolic substances) combined with hyperuricemia in patients who are most at risk for severe COVID-19.
Since the onset of the COVID-19 pandemic, evidence suggests that individuals with obesity, hypertension, metabolic syndrome, insulin resistance, pre-diabetes, diabetes, or chronic kidney disease are most at risk for more severe health consequences.
These individuals have a higher rate of hyperuricemia and endothelial dysfunction. Low-grade systemic inflammation associated with these disease states and pre-existing vascular injury may suppress an individual’s ability to respond with a sufficient response to fight infection and leaves the individual more prone to excessive pro-inflammatory and pro-coagulative state.
The new patent filing proposes compositions of xanthine oxidase inhibitors, uric acid lowering agents and/or anti-viral agents alone or in combination, and methods for enhancing anti-viral therapies for the treatment of individuals most at risk.
A recent study results suggest that uric acid lowering can inhibit COVID-19 replication, a finding that supports the clinical use of uric acid lowering agents to control COVID-19 infection in humans.
Viral load during infection has been reported to be associated with more severe symptoms. Acute kidney injury (AKI) has also been identified as an independent risk factor for in-hospital mortality due to COVID-19 as well as other coronavirus infections.
XORTX Therapeutics Inc. (XRTX) is up 45.45 per cent trading at $2.24 per share as of 3:43 p.m. ET.
